Empresa Asarina Pharma AB (publ) Nasdaq Stockholm
Acciones
SE0011641794
Biotecnología e investigación médica
Resumen de negocios
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Peter Nordkild
CEO | Chief Executive Officer | 69 | 01/01/16 |
Director of Finance/CFO | 69 | 01/04/17 | |
Public Communications Contact | 63 | 01/01/11 | |
Magnus Brisander
PRN | Corporate Officer/Principal | - | - |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Paul de Potocki
CHM | Chairman | 62 | 01/01/18 |
Public Communications Contact | 63 | 01/01/11 | |
Marianne Kock
BRD | Director/Board Member | 69 | 01/01/18 |
Director/Board Member | 50 | 21/01/20 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 22 641 409 | 13 127 611 ( 57,98 %) | 0 | 57,98 % |
Información de la empresa
Asarina Pharma AB
Karolinska Institutet Science Park Fogdevreten 2
171 65, Solna
+46 8 52 48 44 82
http://www.asarinapharma.comSector
Varia. 1 de ene. | Capi. | |
---|---|---|
+11,91 % | 118 mil M | |
+11,60 % | 106 mil M | |
-4,68 % | 24,28 mil M | |
-0,82 % | 21,96 mil M | |
-10,12 % | 18,16 mil M | |
-42,12 % | 16,37 mil M | |
-17,47 % | 15,56 mil M | |
+2,77 % | 13,63 mil M | |
+34,58 % | 12,27 mil M |